Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Cancer MedicineJun 6, 2026
Development and Validation of a Predictive Nomogram for Diagnosing Colorectal Cancer Based on Immune‐Nutritional Score

Clinical Context

We think this might be relevant to the clinical guidance for TNM 8th Ed (Colorectal Cancer).

CancerJun 5, 2026
Site‐ and age‐dependent associations between Fusobacterium nucleatum and colorectal cancer mortality

Clinical Context

We think this might be relevant to the clinical guidance for TNM 8th Ed (Colorectal Cancer).

CancerJun 5, 2026
Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer

Clinical Context

We think this might be relevant to the clinical guidance for TNM 8th Ed (Colorectal Cancer).

TNM 8th (Colorectal)

TNM 8THAJCC Colorectal Staging Framework

Pathologic Classification

Staging Components

  • T: Depth of invasion into lamina propria, submucosa, muscularis propria, or serosa.
  • N: Number of regional lymph nodes (N1: 1-3, N2: 4+) or tumor deposits (N1c).
  • M: Distant metastasis to one (M1a) or multiple (M1b) organs, or peritoneum (M1c).

Therapeutic Outlook

Stage IIA

Management Strategy

Early-stage disease. Surgery alone is often sufficient; adjuvant chemotherapy may be considered for high-risk features.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

All patients with biopsy-proven adenocarcinoma of the colon or rectum.
Initial clinical staging (cTNM) via CT Chest/Abdomen/Pelvis and Rectal MRI.
Pathological staging (pTNM) following surgical resection to determine the need for adjuvant chemotherapy.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the mrTRG (Rectal MRI), MSI/MMR Interpretation or the Fong Clinical Risk Score to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

mrTRG
MSI/MMR Interpretation
Fong Clinical Risk Score
IMWG Myeloma Frailty
Z0011 Eligibility
CNS-IPI
MRD Assessment Framework
PERCIST 2.0
FIGO 2021
CLL-IPI
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.